Volume | 569,882 |
|
|||||
News | (1) | ||||||
Day High | 0.3113 | Low High |
|||||
Day Low | 0.265 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Biosig Technologies Inc | BSGM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.265 | 0.265 | 0.3113 | 0.3025 | 0.2603 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,258 | 569,882 | $ 0.2868779 | $ 163,487 | - | 0.2554 - 1.65 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:15:10 | formt | 100 | $ 0.31 | USD |
Biosig Technologies Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
26.43M | 88.11M | - | 286k | -27.27M | -0.31 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Biosig Technologies News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BSGM Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.3055 | 0.34 | 0.2554 | 0.2861788 | 309,380 | 0.0045 | 1.47% |
1 Month | 0.4462 | 0.545 | 0.2554 | 0.3717375 | 347,487 | -0.1362 | -30.52% |
3 Months | 0.4583 | 0.689 | 0.2554 | 0.4400636 | 263,162 | -0.1483 | -32.36% |
6 Months | 1.54 | 1.58 | 0.2554 | 0.9884708 | 518,618 | -1.23 | -79.87% |
1 Year | 0.4076 | 1.65 | 0.2554 | 1.00 | 450,627 | -0.0976 | -23.95% |
3 Years | 4.59 | 6.14 | 0.2514 | 1.85 | 337,427 | -4.28 | -93.25% |
5 Years | 4.03 | 12.43 | 0.2514 | 4.05 | 349,158 | -3.72 | -92.31% |
Biosig Technologies Description
BioSig Technologiesis an advanced medical technology company bringing never-before-seen insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), BioSig is committed to addressing healthcare¿s biggest priorities-saving time, saving costs, and saving lives. The Company¿s first product, the PURE EP¿ System, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform insight-based, highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy. The global EP market is projected to reach $16B in 2028 with an 11.2% growth rate. |